Coronavirus Latest News

GlaxoSmithKline faces dose of strong medicine from US investor

This week’s lacklustre results will strengthen boss Emma Walmsley’s case for reform – but also inspire her critics

When the American hedge fund Elliott Management took a sizeable stake in GlaxoSmithKline this month, the drugmaker’s shares jumped 5% on speculation of a possible shake-up at the company.

GSK’s chief executive, Emma Walmsley, will face questions over the future of the business, as well as its performance, when she unveils first-quarter results on Wednesday, followed by the annual meeting a week later. Analysts are forecasting a 14% drop in revenues to £7.8bn and a 10% decline in pre-tax profit to £1.7bn in what looks to be the weakest quarter of the year. This reflects tougher year-on-year comparisons (due to stockpiling of many products at the start of the pandemic), as well as rising research and development costs.

Continue reading…

Read the original article at The Guardian

Related Articles

Back to top button
Close